Dec 19 (Reuters) - BioMarin Pharmaceutical (BMRN) said on Friday it would acquire Amicus Therapeutics (FOLD) for about $4.8 billion, expanding its presence in rare metabolic diseases.
The drugmaker will pay $14.50 per share for Amicus, a premium of 33.1% to the stock's last close. Shares of Amicus surged 30%, while BioMarin rose nearly 5% in premarket trading.
The deal strengthens BioMarin's portfolio with Amicus' approved genetic disorder treatments including Galafold, an oral drug for Fabry disease, which is caused by a faulty gene that leads to a buildup of fatty substances in cells.
Amicus also markets a combination therapy Pombiliti and Opfolda for Pompe disease, a genetic condition in which a complex sugar called glycogen builds up in the body's cells.
Amicus also has U.S. rights to DMX-200, a potential treatment of a type of kidney disease known as focal segmental glomerulosclerosis.
BioMarin intends to finance the deal through a combination of cash on hand and about $3.7 billion of non-convertible debt financing.
The company's total cash and investments at the end of September 30 were about $2 billion.
The acquisition, which is expected to close in the second quarter of 2026, will add revenue immediately after the transaction closes, BioMarin said.
The deal is also expected to add to adjusted profit in the first 12 months after close and be substantially accretive beginning in 2027, the company said.
(Reporting by Christy Santhosh and Sriparna Roy in Bengaluru; Editing by Leroy Leo and Maju Samuel)
LATEST POSTS
- 1
RFK Jr.’s vaccine advisers plan biggest change yet to childhood schedule - 2'The best gift ever': Baby is born after the rarest of pregnancies, defying all odds
- 3Can ICE agents detain U.S. citizens? What powers do they have to arrest people? Your most common questions answered.
- 4Wedding Guest Outraged That Bride and Groom, Who Are in Their 60s and Have Both Been Married Before, Registered for Gifts
- 5Vote In favor of Your Favored Treat
- Must-See Attractions in France
- Exclusive-Drugmakers raise US prices on 350 medicines despite pressure from Trump
- 4 astronauts depart ISS, leaving behind just 3 crewmates to staff the orbiting lab
- Alleged Huione Group Money Laundering Boss Extradited to China
- The most effective method to Examine a Cellular breakdown in the lungs Finding with Family
- 10 Work Valuable chances to Assist with supporting Your Advanced degree
- ‘Risk children’s lives for some extra manpower’: IRGC recruits 12 year olds to fill personnel gaps
- AstraZeneca to invest $2 billion as part of US manufacturing push
- Netflix’s Price Hikes Just Got Rejected by an Italian Court. Here’s Why It Matters Everywhere
